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Cotransfection of Vascular Endothelial Growth Factor-A
and Platelet-Derived Growth Factor-B Via
Recombinant Adeno-Associated Virus Resolves
Chronic Ischemic Malperfusion
Role of Vessel Maturation
Christian Kupatt, MD,* Rabea Hinkel, DVM,* Achim Pfosser, MD,* Chiraz El-Aouni, PHD,*
Alexander Wuchrer, MD,* Andrea Fritz, MD,* Franziska Globisch, MD,* Michael Thormann, DVM,*
Jan Horstkotte, MD,* Corinna Lebherz, MD,* Eckart Thein, DVM,† Andrea Banfi, PHD,‡
Peter Boekstegers, MD*
Munich, Germany; and Basel, Switzerland
Objectives We set out to investigate the ability of cardiotropic adeno-associated viral vector (AAV2.9  recombinant adeno-
associated virus [rAAV]) to induce prolonged expression of vascular endothelial growth factor (VEGF)-A and platelet-
derived growth factor (PDGF)-B in a rabbit hindlimb ischemia model and a pig model of hibernating myocardium.
Background Gene therapy to induce angiogenesis and arteriogenesis has produced mixed results. However, long-acting
viruses, such as rAAV, as well as combined induction of angiogenesis and vessel maturation might extend
the therapeutic potential.
Methods In rabbits, 0.5 1011 particles rAAV.VEGF-A with or without 1 1012 particles rAAV.PDGF-B were retroinfused at day 7
after femoral artery excision. At days 7 and 35, collateral counts and perfusion were determined, each value given as the
day 35/day 7 ratio. Capillary-to-muscle fiber ratio was determined at day 35. In pigs, implantation of a reduction stent graft
into the circumflex artery led to complete occlusion at day 28. At this time point, retroinfusion of rAAV.VEGF-A (1 1013
particles), rAAV.VEGF-A/PDGF-B (2 1012 and 4 1012 particles, respectively) or mock transfection was performed. Ejec-
tion fraction and left ventricular end-diastolic pressure were assessed at days 28 and 56.
Results In rabbits, rAAV.VEGF-A strongly induced angiogenesis (capillary-to-muscle fiber ratio; 1.67  0.09 vs. 1.32 
0.11 in rAAV.LacZ-treated limbs, p  0.05), but not collateral growth (125  7% vs. 106  7%, p  NS) or per-
fusion (136  12% vs. 107  9%, p  NS). With VEGF-A/PDGF-B cotransfection, collateral growth increased to
146  9%, perfusion to 163  8% of the respective day 7 value (p  0.05). In the pig model, retroinfusion of
rAAV.VEGF-A/PDGF-B increased regional myocardial blood flow reserve from 101  4% (rAAV.Mock) to 129 
8% (p  0.05), based on collateral growth (3.2  0.3 in rAAV.Mock vs. 9.0  0.4 in rAAV.VEGF-A/PDGF-B,
p  0.05), whereas rAAV.VEGF-A did not alter flow reserve (112  7%) or collateral count (5.2  0.7). rAAV.VEGF-A/
PDGF-B improved ejection fraction (55  5% vs. 34  3% in rAAV.Mock, p  0.05) unlike rAAV.VEGF-A (37  2%).
Conclusions Retroinfusion of rAAV.VEGF-A alone induces angiogenesis, but fails to enhance collateralization and perfusion,
unless PDGF-B is cotransfected. In addition to neovascularization, rAAV.VEGF-A/PDGF-B improves regional and
global myocardial function in hibernating myocardium. (J Am Coll Cardiol 2010;56:414–22) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.050a
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July 27, 2010:414–22 rAAV.VEGF-A/PDGF-B Improves Hibernating Myocardiumndothelial growth factor (VEGF)-A have been demon-
trated to increase small-vessel density and, although not
lways, perfusion (1). However, initial clinical trials with
ocal delivery of angiogenic growth factors by adenoviral
ectors yielded mixed results (2). Prominent among the
any reasons are the efficacy of growth factor transfection,
uration of expression, and the choice of agent(s) mediating
ascular growth.
Therapeutic neovascularization appears to require the
nvolvement of both microvascular and macrovascular pro-
esses. At the microcirculatory level, angiogenesis is defined
s sprouting and growth of capillaries, which, however,
egress after cessation of VEGF-A stimulation if pericytes
ave not been recruited (3). Therefore, stabilization of
ewly created capillary networks by mural cells (pericytes),
nown to be recruited by platelet-derived growth factor
PDGF)-B (4,5), is essential for therapeutic neovasculariza-
ion. Insufficient recruitment of pericytes to newly formed
apillaries and impaired maturation has been observed with
ncontrolled VEGF-A overexpression (6–8), inducing at
imes leaky vessels (9) and even hemangioma growth (8,10).
onsistent with these observations, VEGF-A has been
dentified as the major factor driving tumor angiogenesis
11), where vascularization is characterized by an irregular
nd often immature pattern (12). Of note, we recently
ound that PDGF-B coexpression can restore proper mat-
ration of VEGF-A–induced microvessels, preventing
emangioma formation and increasing vessel functionality
A. Banfi et al., unpublished data, July 2009).
In addition to angiogenesis, arteriogenesis of collateral
essels, a distinct process of neovascularization, is necessary
o reach therapeutic improvement of blood perfusion and
uscle function. VEGF-A alone is not as efficient in
nducing collateral growth (13,14) as other proarteriogenic
and proinflammatory) cytokines, such as monocyte che-
oattractant protein-1, which act through monocyte re-
ruitment (15).
Insufficient capillary maturation and paucity of arterio-
enesis may partly explain the therapeutic failure of
EGF-A in clinical trials (16). Both processes require
ural cell recruitment mediated by PDGF-B (4,6,17).
o test the hypothesis that PDGF-B and mural cell
ecruitment can increase the therapeutic efficacy of
EGF-A, we conducted the present study using long-
cting adeno-associated vectors encoding the cDNA of
EGF-A and PDGF-B to induce therapeutic neovascu-
arization in large-animal models of limb and cardiac
hronic ischemia.
ethods
ll chemicals were purchased from Sigma (Taufkirchen,
ermany), if not stated otherwise. Contrast agent Solutrast
70 was provided by Byk Gulden (Konstanz, Germany).
irus production. The recombinant recombinant adeno-ssociated virus (rAAV). VEGF-A, rAAV.PDGF-B, and (AAV.LacZ vectors were produced
sing a triple transfection method,
plasmid encoding for the trans-
ene (VEGF-A, PDGF-B, or
acZ) under control of a cyto-
egaly virus promoter flanked by
he cis-acting AAV2 internal ter-
inal repeats, a second plasmid
roviding AAV2 rep, and AAV9
ap in trans (18), whereas a third
lasmid supplemented adenoviral
elper function. Transfection was
erformed in 293 cells using poly-
thylenimine. Cells were harvested
8 h later and vectors purified with cesium gradients as
escribed previously (19). Viral titers were determined using
eal-time polymerase chain reaction against the polyA
ail of the vector bGH. Forward primer sequence was
=-tctagttgccagccatctgttgt-3= reverse primer sequence was
=-tgggagtggcaccttcca-3=. As mock vector, we packaged
he AAV without any coding sequence (rAAV.Mock) for
ransfection in the heart. This avoided potential func-
ional interference due to an overexpressed reporter
rotein. Trans and helper plasmids were kindly provided
y James M. Wilson, University of Pennsylvania.
ene transfer detection. Real-time polymerase chain re-
ction was used for virus detection in transfected rabbit
issue. Primer sequences for VEGF-A were forward
=TTTTACGCTATGTGGATACGC and reverse
=GAGACAGCAACCAGGATTT; primer sequences for
DGF-B were forward 5=CCTCATAGACCGCACCAA
nd reverse 5=CGCACAATCTCGATCTTTCT. Real-
ime polymerase chain reaction was performed using SYBR
reen (Bio-Rad, Munich, Germany) for 40 cycles (30 s at
5°C, 30 s at 58°C, 30 s at 72°C) in an iQ-Cycler
Bio-Rad). Moreover, in the rabbit and pig model,
EGF-A and PDGF-B were detected by immunoblotting
Santa Cruz, Heidelberg, Germany) (20).
nimal protocols. All animal experiments were approved
y the Bavarian Animal Care and Use Committee (AZ
11-2531-2531-82/02 and AZ 55.2-1-54-2531-67/07) and
onformed to the Guide for the Care and Use of Laboratory
nimals published by the U.S. National Institutes of Health
NIH publication no. 85-23, revised 1996, Approved Insti-
ution #A5637-01). All animal experiments were conducted
t the Walter-Brendel Centre of Experimental Medicine.
abbit protocol. At day 0, New Zealand white rabbits
3.5  0.4 kg, 6 per group for rAAV.LacZ and 5 each for
AAV.VEGF-A and rAAV.VEGF-A/PDGF-B) were
nesthetized and subjected to excision of the complete right
emoral artery (Online Fig. 1A) (21). At days 7 and 35, an
ngiography was performed after local infusion of adenosine
500 g per animal) using automated contrast agent injec-
ion (1 ml/s, 4 ml total). Twenty-five angiographic frames
er second were acquired and stored for later analysis
Abbreviations
and Acronyms
LV  left ventricular
PDGF  platelet-derived
growth factor
rAAV  recombinant
adeno-associated virus
rAAV.Mock  recombinant
adeno-associated virus
without any coding
sequence
VEGF  vascular
endothelial growth factorZiehm, Nürnberg, Germany).
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rAAV.VEGF-A/PDGF-B Improves Hibernating Myocardium July 27, 2010:414–22At day 7, the tibial anterior vein was surgically prepared
nd a polyethylene catheter was inserted. A ligature was
laced around the femoral vein, gently closed, and fluoro-
copic control of occlusion of venous outflow was performed
Online Fig. 1A). Thereafter, retroinfusion of 5 ml of
hosphate-buffered saline containing 0.5 1011 particles of
AAV.LacZ or rAAV.VEGF-A with or without 1  1012
articles rAAV.PDGF-B was performed over 30 min at
0-mm Hg perfusion pressure.
apillary density. Tissue samples from calf muscles (gas-
rocnemius, tibialis anterior, fibularis) were obtained for
uantification of capillary density. Tissue was fixed in
ormaldehyde and embedded in paraffin. Capillaries stained
y CD31 antibody SC1506 (Santa Cruz) and myofibers
ere counted in a blinded fashion in 5 microscopic fields
40 magnification) per muscle. NG-2 antibody (Chemi-
on, Hofheim, Germany) was used for pericyte detection.
ollateral growth, perfusion. Collaterals were assessed in
blinded fashion by counting the number of vessels in the
emoral region intersecting an overlaying grid, as described
reviously (22). For assessment of perfusion, fluorescent
icrospheres were injected by a catheter into the left
entricle over 30 s. Arterial reference blood samples were
rawn at a fixed rate. At the end of the experiment, samples
ere taken from thigh and calf muscles to assess blood flow
n the upper and lower region of the ischemic hind limb and
he nonischemic contralateral limb. After lysis, microsphere
uorescence was quantified in a Tecan Safire microplate
eader, using the appropriate detection wavelength for each
uorescent microsphere type according to manufacturer’s
nstructions.
ig experiments. German farm pigs were anesthetized and
nstrumented as previously described (20). Briefly, ischemia
as induced by placing a reduction stent (2.5  13 mm,
omed, Munich, Germany) (23) into the proximal ramus
ircumflexus, inducing 75% stenosis that progressed to total
cclusion at day 28 (Online Fig. 1B). A marker of gradual
tent occlusion and an inclusion criterion was an area of
nfarcted myocardium6% of the total left ventricular (LV)
rea at d56 (tetrazolium red staining). Infarct size was 3.1
.1% for rAAV.Mock, 2.4  0.8% for rAAV.VEGF-A,
nd 2.1  0.4% in the rAAV.VEGF-A/PDGF-B group.
f 27 animals entering the study after stent placement, 8
ied due to sudden cardiac death during the first 28 days,
hereas no animal died between days 28 and 56. Two
nimals were excluded because of myocardial infarction
6% of the LV mass. The remaining 17 animals were
reated by mock transfection (6 1012 rAAV containing no
ransgene, n  7), rAAV.VEGF-A transfection (1  1013
articles, n 4), or rAAV.VEGF-A/PDGF-B transfection
2  1012 and 4  1012 particles, respectively, n  6) via
ontinuous pressure-regulated retroinfusion into the lateral
ein, as described previously (20).
At day 56, subendocardial segment shortening was per-
ormed after placing sonomicrometry crystal pairs into the
schemic (circumflex artery perfused area) region and nor- ialized to measurements in the control region (left anterior
escending artery perfused area). Global myocardial func-
ion was assessed by means of a pressure tip catheter placed
n the left ventricle (for LV end-diastolic and systolic
ressures, dP/dtmax, dP/dtmin), whereas LV angiography
as performed in anteroposterior position for the analysis of
jection fraction (yielding slightly smaller control values
han a right anterior oblique view). Although one animal of
he treatment group died during SES assessment, it pro-
ided all other data.
For assessment of regional myocardial blood flow, fluo-
escent microspheres (Molecular Probes, 5  106) were
njected into the left atrium at each time point (day 28, day
6) at rest and during rapid pacing (150 beats/min), and
ppropriate reference blood samples were drawn. Systematic
ampling of LV myocardium (23) revealed perfusion levels
t baseline and rapid atrial pacing (140 beats/min, flow
eserve) in the ischemic and nonischemic areas. Postmortem
ngiograms were obtained for visualization of collateral
ormation. Tissue from nonischemic and ischemic LV
yocardium was used for determining the capillary-to-
uscle fiber ratio (see previous text).
tatistical methods. The results are given as mean 
EM. Statistical analysis of the results between 2 exper-
mental groups was performed with 1-way analysis of
ariance, where appropriate, whereas 2-way analysis of
ariance was applied in all figures that compared 2 groups
n1 condition. Whenever a significant effect was obtained
ith analysis of variance, we performed multiple compari-
on tests between the groups using the Student-Newman-
eul procedure. Two experimental groups were compared
sing Student t test. All procedures were performed using
PSS version 17.0.2 (SSPS, Inc., Chicago, Illinois). Dif-
erences between groups were considered significant at
 0.05.
esults
n the rabbit model of chronic hindlimb ischemia, rAAV
elivery yielded a robust transduction of muscle tissue, as
etected by LacZ reporter gene expression 4 weeks later
Online Fig. 2A). Transfection occurred throughout the
reated hindlimb (i.e., in both the calf and thigh muscles).
pproximately one-fifth of the hindlimb production rate
as obtained in terms of polymerase chain reaction for the
iver and 1/20 for the spleen and the kidneys (data not
hown). Consistently, increased expression of VEGF-A and
DGF-B transcripts was detected in the ischemic hindlimb
issue 35 days after treatment with the therapeutic AAV
ompared with rAAV.Mock vector (Online Figs. 2B and
C). Although no elevation of plasma levels of VEGF-A
as detected by enzyme-linked immunosorbent assay,
DGF-B was found elevated at day 35 (from 1.2  0.1
g/ml to 2.1  0.1 ng/ml, data not shown).
To assess the effects of PDGF-B coexpression on VEGF-nduced angiogenesis, 0.5  1011 rAAV.VEGF-A particles
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July 27, 2010:414–22 rAAV.VEGF-A/PDGF-B Improves Hibernating Myocardiumere retroinfused into the ischemic hindlimbs with or
ithout 1  1012 rAAV.PDGF-B particles. VEGF-A
lone caused an increase in capillary-to-muscle fiber ratio
rom 1.32  0.11 to 1.67  0.09 (p  0.05) compared with
ontrol LacZ virus (Figs. 1A and 1B), although the induced
etwork appeared slightly irregular (Fig. 1A). Moreover, a
arge proportion of vessels induced by VEGF alone were
mmature, as indicated by the lack of coverage with NG-
–positive pericytes (Figs. 1C and 1D). Codelivery of the
AAV.VEGF-A/PDGF-B combination did not further
ncrease the capillary-to-muscle fiber ratio (1.73  0.04)
n the calf musculature compared with VEGF-A alone
Figs. 1A and 1B), but significantly increased pericyte coverage
f the induced vessels (p  0.02) (Figs. 1C and 1D).
The functional effects of rAAV delivery were determined
y quantifying collateral artery growth and vascular perfu-
ion in ischemic hindlimbs at the time of treatment (day 7)
nd after 4 weeks (day 35). Angiographic analysis (repre-
entative examples are shown in Fig. 2A) demonstrated that
AAV.VEGF-A alone did not induced growth of collateral
rteries compared with rAAV.LacZ (125  8% vs. 106 
% for rAAV.LacZ, each compared with the respective level
t day 7; p  NS), whereas the collateral growth was
ignificantly increased by codelivery of PDGF-B (146 
%, p  0.05 vs. rAAV.LacZ) (Fig. 2B). Consistent with
Figure 1 VEGF-A/PDGF-B Transfection Induces Angiogenesis a
Examples (A) and quantification (B) of PECAM-1 staining for capillary detection re
factor (VEGF)-A and VEGF-A/platelet-derived growth factor (PDGF)-B transfected
1–positive vascular structures with pericytes (detected by NG-2 antibody) was i
hindlimbs (yellow bar  50 m). (D) Quantitative analysis confirmed that capi
virus (rAAV).VEGF-A/PDGF-B transfection.he lack of collateral growth, perfusion was not enhanced by tAAV.VEGF-A alone (128  11% vs. 110  6% for
AAV.LacZ, each compared with the respective level at
ay 7, p  NS), but it was greatly improved when
AAV.PDGF-B was coapplied (189  14%, p  0.05 vs.
oth, rAAV.VEGF-A and rAAV.LacZ) (Fig. 2C). Thus,
nly the combination of VEGF-A and PDGF-B induced
oth microvascular and macrovascular growth (i.e., genera-
ion of pericyte-covered capillaries and an increase in
ollaterals, with a subsequent improvement of perfusion).
To prove the therapeutic relevance of the VEGF-A/
DGF-B combination also in cardiac ischemia, we next
nvestigated its impact on a preclinical model of chronic
yocardial hibernation in pigs. A reduction stent was used to
radually induce chronic total occlusion of the target coronary
rtery and hibernating myocardium at 4 weeks. At this time
oint, either an empty vector control (rAAV.Mock),
AAV.VEGF-A alone, or the rAAV.VEGF-A/PDGF-B
ombination was retroinfused via the lateral vein. Western blot
nalysis confirmed sustained overexpression of VEGF-A and
DGF-B protein 4 weeks after treatment with rAAV.VEGF-
/PDGF-B compared with rAAV.Mock (Online Figs. 3A
nd 3B). At day 56, the combined treatment caused a signif-
cant increase in both capillary density (detected by PECAM-1
taining) and pericyte coverage (detected by NG-2 staining) in
icrovessel Maturation in Rabbit Hindlimbs
n increased capillary/muscle fiber ratio in both vascular endothelial growth
ls (yellow bar  200 m). (C) As depicted in examples, coverage of PECAM-
ed after combined VEGF-A/PDGF-B treatment compared with LacZ-transfected
ensity and pericyte coverage increased after recombinant adeno-associatednd M
veals a
anima
ncreas
llary dhe ischemic region (Fig. 3). Of note, VEGF-A alone, al-
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rAAV.VEGF-A/PDGF-B Improves Hibernating Myocardium July 27, 2010:414–22hough inducing a 2.1-fold increase in capillary density, failed
o increase pericyte recruitment (Fig. 3B).
Similarly, the number of angiographically visible collat-
rals was greatly increased in the VEGF-A/PDGF-B–
reated group (9.0  0.4) compared with the rAAV.Mock
roup (2.7  0.5, p  0.001) (Figs. 4A and 4B), whereas
EGF-A transduction caused only a modest, although
ignificant, increase (Fig. 4B). The Rentrop score (24) of
Figure 2 VEGF-A/PDGF-B Escalates Collateral Growth and Perf
Examples (A) and quantification (B) of collateral count (see Methods section) reve
(C) Fluorescent microsphere analysis revealed an increase in blood flow only after
Figure 3 VEGF-A/PDGF-B Induces Angiogenesis and Vessel Ma
Examples (A) and quantification (B) of PECAM-1 (endothelial cells) and NG-2 (peri
rAAV.Mock, rAAV.VEGF-A (1  1013 particles), or rAAV.VEGF-A/PDGF-B (2  1012/unctioning collaterals (0  no filling, 1  side branch
lling, 2  partial main vessel filling, 3  complete main
essel filling) also indicated a pronounced effect of the
EGF-A/PDGF-B combination (2.4  0.2 vs. 1.1  0.2,
 0.02), whereas VEGF-A alone exerted no effect
Fig. 4C). Consistent with the assessment of collateral
evelopment, quantification of blood flow by fluorescent
icrospheres indicated an attenuation of perfusion in the
in Rabbit Hindlimbs
at VEGF-A increases collateral growth only if combined with PDGF-B.
ection of both VEGF-A/PDGF-B (5 per group). Abbreviations as in Figure 1.
ion in Hibernating Myocardium (Pigs)
xpression in ischemic myocardium after transfection with
12 particles) (yellow bar  50 m). Abbreviations as in Figure 1.usion
als th
transfturat
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July 27, 2010:414–22 rAAV.VEGF-A/PDGF-B Improves Hibernating Myocardiumerritory of the circumflex artery in rAAV.Mock and
EGF-A virus-treated hearts, which was completely alle-
iated by treatment with rAAV.VEGF-A/PDGF-B (77 
%, 85  2% vs. 97  5% of resting nonischemic tissue,
espectively, p  0.04) (Fig. 4D). To quantify the perfusion
eserve of myocardial tissue, blood flow was also measured
Figure 4 Collateralization and Blood Flow Increase After VEGF-
Examples (A) and quantification (B) of angiographically visible collaterals in Mock-
vs. Mock). (C) Rentrop score indicates a gain of functional collateralization only af
of the ischemic myocardium at rest (D) and under rapid pacing (150/min) (E) bea
alone. Abbreviations as in Figure 1.uring atrial pacing at 150 beats/min (Fig. 4E). Perfusion fleadily increased in nonischemic tissue (144 6% of resting
onischemic myocardium, p 0.002). In contrast, ischemic
issue was unable to increase perfusion beyond resting values
n the rAAV.Mock group (101  4%), revealing a signifi-
antly impaired coronary flow reserve (p  0.002). Hearts
reated with rAAV-VEGF-A tended to improve coronary
GF-B Transfection of Pigs
GF-A/PDGF-B transfected pigs (arrows indicate collateral formation, #p  0.05
GF-A/PDGF-B transfection. Microsphere analysis revealed a decreased perfusion
ich was corrected by transfection with rAAV.VEGF-A/PDGF-B, but not with VEGF-AA/PD
or VE
ter VE
ts, whow reserve (112  7% in the ischemic area vs. 147  12%
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rAAV.VEGF-A/PDGF-B Improves Hibernating Myocardium July 27, 2010:414–22n nonischemic tissue, p  0.055). Of note, a gain in
oronary flow reserve in the ischemic myocardium was
ound in the rAAV-VEGF-A/PDGF-B group (128 12%
s. 137  10% in nonischemic tissue, p  NS. vs.
onischemic tissue, p  0.05 vs. the rAAV.Mock group).
Finally, we verified whether the restoration of regional
lood flow after transfection with rAAV.VEGF-A/
DGF-B could improve global myocardial function. Al-
hough LV end-diastolic pressure did not change signifi-
antly over 4 weeks with rAAV.Mock (17.1 1.2 to 19.4
.0 mm Hg) or rAAV.VEGF-A treatment (15.5  0.6 to
5.8 0.8 mm Hg), combined treatment of rAAV.VEGF-A/
DGF-B reduced LV end-diastolic pressure in the same
eriod from 16.8  0.9 to 12.9  0.9 mm Hg (p  0.01)
Fig. 5A). Moreover, combined treatment improved ejec-
ion fraction from 35.8  2.6% to 55.4  4.1% (p  0.05),
hereas no statistically significant alteration was observed
ither in the mock- (from 38.1  2.3% to 33.7  2.8%) or
he VEGF-A treated group (32.2  1.9% to 37.2  2.1%)
Fig. 5B). Accordingly, the contraction velocity dP/dtmax
as altered only by VEGF-A/PDGF-B (1,731  104 mm
g/s vs. 1,337  67 mm Hg/s in rAAV.Mock at rest), but
ot by VEGF-A therapy (1,275  145 mm Hg/s) (Online
ig. 4A). Relaxation velocity showed the same improvement
dP/dtmin: 1,854  127 mm Hg/s in the VEGF-A/
Figure 5 VEGF-A/PDGF-B Transfection Resolves Dysfunction of
(A) Left ventricular end-diastolic pressure (LVEDP), a parameter reflecting global m
treated hearts. (B) Accordingly, ejection fraction (EF), which was depressed in all g
0.05 vs. day 28 level). (C) Subendocardial segment shortening of the lateral left v
at rest and deteriorated further under rapid pacing (§p  0.05 vs. baseline). Of no
LAD  left anterior descending artery; SES  subendocardial segment shorteningDGF-B group vs.1,206 174 mm Hg/s and1,080 f9 mm Hg/s in the rAAV.Mock and rAAV.VEGF-A
roups, respectively) (Online Fig. 4B). To quantify the
unctional reserve of the ischemic myocardium, analysis
f regional shortening of the LV lateral wall by sono-
icrometry was performed at rest and at increasing heart
ates. As shown in Figure 5C, subendocardial segment
hortening in mock-treated hearts was severely impaired
t baseline (40  7% of the nonischemic rAAV.Mock
evel) and steadily declined during pacing, arriving at 9 
% at 150/min (p  0.05). VEGF-A transduction of the
schemic myocardium did not alter this behavior sig-
ificantly (42  4% at baseline to 24  4% at 150
eats/min, p  0.05). In contrast, combined treatment
ith rAAV.VEGF-A/PDGF-B caused a trend toward
unctional improvement at rest (64  9%, p  0.07 vs.
AAV.Mock and rAAV.VEGF-A) and statistically sig-
ificant benefit at 150 beats/min (53  11%, p  0.05).
iscussion
n the present pre-clinical study, we used a long-acting
ector (AAV) as a means to ensure long-term efficacy of
ransduction. Moreover, we sought to overcome the weak-
ess of VEGF-A with respect to inducing vessel maturation
nd collateral growth by combining it with PDGF-B, a
rnating Myocardium
ial function, decreased from day 28 to day 56 only in rAAV.VEGF-A/PDGF-B–
at day 28, exclusively increased after rAAV.VEGF-A/PDGF-B transfection. (*p 
lar wall, assessed by sonomicrometry (see Methods section), was compromised
AV.VEGF-A/PDGF-B transfection blunted this effect. (*p  0.05 vs. rAAV.Mock).
abbreviations as in Figure 1.Hibe
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roups
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July 27, 2010:414–22 rAAV.VEGF-A/PDGF-B Improves Hibernating Myocardiumperipheral artery occlusion model, we found that the
EGF-A/PDGF-B combination did not alter the capillary
ensity induced by VEGF-A alone (Figs. 1A and 1B).
owever, pericyte coverage of capillaries as well as growth of
he conductance vessels (collaterals) increased significantly after
DGF-B cotransduction (Figs. 1C, 1D, 2A, and 2B), en-
bling a gain in limb perfusion. Combined VEGF-A/
DGF-B gene therapy was also found capable of improving
he function of hibernating myocardium in a large-animal
odel (pigs) of chronic ischemia, in contrast to VEGF-A
lone, even though the latter was given at a 5-fold higher dose
1 1013 virus particles vs. 2 1012 in the combined group).
gain, increased angiogenesis, pericyte coverage, and col-
ateral growth were hallmarks of the combined treatment
Figs. 3 to 5). Earlier gene therapy studies for induction of
ngiogenesis and/or arteriogenesis frequently used adenovi-
uses (i.e., vectors capable of intense early efficacy followed
y subsequent silencing by the immune system) rendering
epeated applications inefficient (25). The intensity of early
ector activity may also account for side effects such as
rregular capillary network formation (26), potentially
arming the residual muscle perfusion and preventing
ssential collateral growth (13,27). Moreover, adenoviral
EGF-A transduction failed to increase calf capillary
ensity 20 days later, suggesting that vessel regression
akes place as a result of short duration of expression (26).
In contrast, if delivered by an AAV, which provides a
elayed but prolonged gene expression, VEGF-A was
apable of inducing a lasting gain in perfusion (28). How-
ver, at the high dose used in that study in the rat hindlimb
1.8  1013 virus particles), contamination of noninjected
rgans such as the brain and testis was found, and muscles
ecreted VEGF-A readily even after isolation and in vitro
ultivation. In our rabbit study using a 360-fold lower virus
ose in a 10-fold larger animal, no serum contamination
as found (data not shown), whereas reporter gene activity
ndicated continued muscle cell expression until the end of
he observation period. When we applied higher doses (1 
013 virus particles), VEGF-A was able to initiate collater-
lization in the rabbit model (data not shown). In that case,
e did not observe hemangioma formation, but found
emote target gene expression in the contralateral limb,
iver, spleen, and kidney, consistent with a low, but detect-
ble LacZ expression in the rAAV.LacZ group in these
rgans.
In an attempt to increase safety of a long-acting vector,
e used a low dose of 0.5  1011 virus particles, at which
EGF-A alone was unable to improve capillary pericyte
overage and collateralization in chronically ischemic hind-
imbs (Figs. 1D and 2B). The mechanisms behind this
mmature vessel growth include high and dishomogeneous
EGF-A levels (inducing irregular capillary networks) (6),
s well as a lack of pericyte recruitment (leading to increased
ascular permeability). Greenberg et al. (7) recently dem-
nstrated that this effect of VEGF-A is caused by
EGF-R2 mediated inhibition of PDGF-R. pTo overcome this lack of efficacy, we added a vector
xpressing the maturation factor PDGF-B (17,29,30).
hen applied via retroinfusion, the combination of low-
ose VEGF-A (0.5  1011 virus particles) and medium-
ose PDGF-B (1  1012 particles) not only restored
apillary maturation by pericyte coverage, without alter-
ng the capillary density compared with VEGF-A alone
Figs. 1B to 1D), but also significantly increased collat-
ralization. The result was a profound improvement in
erfusion. The effect of PDGF-B on collateral arteries
ay arise from 2 possible causes: First, the functionally
mproved microcirculation may activate collateral growth
hrough increased flow and shear stress, a powerful
riving force of arteriogenesis (31) that is also observed in
he instance of angiopoietin-1 combined with VEGF-A
32,33). Second, a direct effect of PDGF-B on collateral
rowth cannot be excluded, although this effect appears
eaker than that of monocyte chemoattractant protein-1
r basic fibroblast growth factor (30). It should be noted
hat retroinfusion allows homogeneous transduction of
he thigh muscles where local stimulation of collateral
rowth takes place (34).
Applying the VEGF-A/PDGF-B combination approach
o a pig model of hibernating myocardium, we retroinfused
size-adapted VEGF-A dose (2  1012 virus particles for
40-kg animal), with only double the PDGF-B dose (4 
012 virus particles) because a high dose of PDGF-B might
rovoke coronary restenosis formation in the heart (35).
he efficacy of the given amount of VEGF-A/PDGF-B
as ensured by documentation of increased capillary and
ollateral counts as well as pericyte coverage (Figs. 3B and 4B).
hese effects resulted in an increase of myocardial perfusion
nd function at rest and rapid atrial pacing (Figs. 4D, 4E,
nd 5A to 5C). In comparison, a 5-fold higher dose
f VEGF-A (1013 virus particles) could not increase
ollateralization or perfusion, nor improve cardiac func-
ion (Figs. 4 and 5), although angiogenesis was efficiently
nduced (Fig. 3B). This latter finding suggests that
apillary density itself is insufficient to resolve hibernat-
ng myocardium.
onclusions
e studied the efficacy of rAAV-mediated transfer of the
enes of VEGF-A and PDGF-B for inducing functionally
elevant therapeutic neovascularization after peripheral ar-
erial and coronary artery occlusion. We found that the
ombination of VEGF-A and PDGF-B exceeded the
fficacy of VEGF-A alone, particularly with respect to
icrovascular maturation and collateral growth, resulting in
significant gain in perfusion and (in the heart model)
uscle function. Because the VEGF-A levels chosen were
ow and no alteration of circulating VEGF levels was found,
he combination of VEGF-A and PDGF-B with a long-
asting vector may be therapeutically rewarding in no-option
atients with chronic peripheral or cardiac ischemia.
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